Effects of Botulinum Toxin Type A and Argireline on Dermal Collagen Remodeling and Skin Biology in a Flap Model.
BoNT-A alters collagen composition without improving flap survival, and Argireline showed no detectable tissue-level effects in this study.
Where it sits
this study against the rest of the argireline corpusSummary and findings
This study evaluated the effects of Botulinum toxin type A (BoNT-A), Argireline, and their combination on dermal collagen type I/III and Substance P expression in a flap model using forty female Wistar rats. Subdermal injections were administered one week before flap elevation, and flap survival was quantified on day 10. The results indicated that BoNT-A shifted collagen composition without improving flap survival, while Argireline produced no detectable tissue-level effect.
Abstract
<h4>Background</h4>Botulinum toxin type A (BoNT-A) is increasingly recognized for tissue-level effects beyond neuromuscular blockade, but its impact on dermal collagen composition remains incompletely characterized. Acetyl hexapeptide-8 (Argireline) is a SNAP-25 mimetic cosmeceutical peptide whose biological activity at the tissue level is unclear. This study evaluated the effects of BoNT-A, Argireline, and their combination on dermal collagen type I/III and Substance P (SP) expression in a flap model.<h4>Methods</h4>Forty female Wistar rats were allocated to four groups (n = 10): saline control, BoNT-A, Argireline, and BoNT-A + Argireline. Subdermal injections were administered at six points one week before elevation of a 9 × 3 cm caudally based McFarlane flap. Flap survival was quantified on day 10 using planimetric analysis. Collagen type I/III was assessed using picrosirius red staining under polarized light, and SP expression was evaluated immunohistochemically.<h4>Results</h4>Flap survival did not differ significantly among groups (p = 0.327). Collagen composition differed significantly: BoNT-A-containing groups demonstrated lower type I and higher type III collagen compared with control and Argireline groups (p < 0.001). Argireline alone produced a collagen profile indistinguishable from control. SP expression was significantly elevated in the combination group compared with control and Argireline (p = 0.002).<h4>Conclusions</h4>BoNT-A shifted dermal collagen toward a less mature profile without improving flap survival. Injectable Argireline produced no detectable tissue-level effect under the tested conditions. Increased Substance P expression in the BoNT-A-containing groups represents an exploratory, predominantly BoNT-A-associated neurogenic signal warranting dedicated study. These findings highlight a dissociation between macroscopic tissue viability and dermal remodeling responses.<h4>No level assigned</h4>This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Background
The study addresses the impact of Botulinum toxin type A (BoNT-A) and Argireline on dermal collagen composition, which is not fully characterized in existing literature. Previous studies have highlighted BoNT-A's effects beyond neuromuscular blockade, but its influence on collagen remodeling remains unclear. Understanding these effects is crucial for evaluating the potential cosmetic applications of these agents.
Methods
Forty female Wistar rats were allocated to four groups (n = 10): saline control, BoNT-A, Argireline, and BoNT-A + Argireline. Subdermal injections were administered at six points one week prior to the elevation of a 9 × 3 cm caudally based McFarlane flap. Flap survival was quantified on day 10 using planimetric analysis, while collagen type I/III was assessed using picrosirius red staining under polarized light.
Results
Flap survival did not differ significantly among groups (p = 0.327). Collagen composition differed significantly: BoNT-A-containing groups demonstrated lower type I and higher type III collagen compared with control and Argireline groups (p < 0.001). SP expression was significantly elevated in the combination group compared with control and Argireline (p = 0.002).
Interpretation
The findings indicate that while BoNT-A alters collagen composition, it does not enhance flap survival, suggesting a disconnect between tissue viability and collagen remodeling. The effect sizes reported are statistically significant, but the clinical implications remain uncertain, particularly given the rodent model used. The study's limitations, including small sample size and lack of human data, warrant caution in translating these findings to clinical practice.
Key findings
- Flap survival did not differ significantly among groups (p = 0.327).
- BoNT-A-containing groups demonstrated lower type I and higher type III collagen compared with control and Argireline groups (p < 0.001).
- Argireline alone produced a collagen profile indistinguishable from control.
- SP expression was significantly elevated in the combination group compared with control and Argireline (p = 0.002).
Limitations
- small n=10 per group
- rodent model, may not translate to humans
- no human data provided
- short follow-up of 10 days